Oral Anavex 2-73 Safely Eases Rett Symptoms, Severity in Phase 3 Trial
Anavex 2-73 (blarcamesine), Anavex Life Sciences’ investigational oral therapy, safely and effectively eased the characteristic behavioral features and severity of Rett syndrome in treated women, while improving their quality of life, according to top-line data from the Phase 3 AVATAR trial. The findings, indicating that the trial met its…